KRM Ayurveda Ltd
KRM Ayurveda Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q4 FY26 call signalled
3 of 3 strong
The short version
KRM Ayurveda targets a minimum 50% year-on-year revenue growth over the next few years. KRM Ayurveda Limited expects a minimum of 50% year-on-year revenue growth over the next few years driven by: - Addition of approximately 1,500 to 2,000 beds over the next 3 years.
From KRM Ayurveda Ltd's Q4 FY26 earnings-call transcript · updated 23 Sept 2026.
Revenue & Sales Performance
- KRM Ayurveda targets a minimum 50% year-on-year revenue growth over the next few years.
- Growth drivers include adding approximately 1,500 to 2,000 beds over the next three years across India.
- Plans to open around 100 super-specialty clinics within three years, enhancing disease-specific treatments and increasing patient inflow.
- Expansion includes 30 new clinics in the current year and increasing bed capacity from ~235 to 500 beds by year-end.
- Telemedicine expansion with a new 500-seater center to double revenue from products and services.
- Product sales will grow alongside clinic and hospital expansion, supported by e-commerce launches.
2 more points management made on revenue & sales performance
Profitability & Margins
See what KRM Ayurveda Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Planning to add approximately 2,000 beds over the next 3-4 years with a cost around ₹2 lakh per bed (Page 24).
- Expansion plans include adding 1500 to 2000 beds pan-India and opening about 100 super-specialty clinics over the next three years (Page 15).
- Expect to increase bed capacity from 235 to 500 beds in FY27, with finalized agreements for additional 100-bed hospital in Gurgaon (Page 15).
- Building a 500-seater telemedicine center operational in 1 to 1.5 years to support expansion (Page 22).
- New luxury hospital of 25 beds being developed in Delhi, with scope for expansion (Page 13).
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what KRM Ayurveda Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
- Morepen Laboratories Ltd (Q4 FY26)
472 crore, up 22% year-on-year (YoY) from Rs. Key concall takeaways from Morepen Laboratories Ltd's Q4 FY26 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY26)
202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key concall takeaways from Anuh Pharma Ltd's Q4 FY26 earnings call — and how it ranks against…
- Themis Medicare Ltd (Q4 FY26)
Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key concall takeaways from Themis Medicare Ltd's Q4 FY26 earnings call…
Frequently Asked Questions
What were KRM Ayurveda Ltd Q4 FY26 results?
KRM Ayurveda targets a minimum 50% year-on-year revenue growth over the next few years. KRM Ayurveda Limited expects a minimum of 50% year-on-year revenue growth over the next few years driven by: - Addition of approximately 1,500 to 2,000 beds over the next 3 years.
What is KRM Ayurveda Ltd share price analysis?
KRM Ayurveda Ltd currently shows a strong growth signal based on ranking data. The stock trades at a P/E of 26.4 with a market cap of ₹664 Cr. Investors should review the full earnings analysis for detailed insights.
Is KRM Ayurveda Ltd planning capital expenditure?
Planning to add approximately 2,000 beds over the next 3-4 years with a cost around ₹2 lakh per bed (Page 24).
Keep KRM Ayurveda Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.